Alpha 2.0
Login Register
» Authors » Guy Jerusalem

Guy Jerusalem

Explore the profile of Guy Jerusalem including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 168
Citations 6150
Followers 0
Related Specialties
Oncology
Geriatrics
General Medicine
Top 10 Co-Authors
Hans Wildiers
Claire Josse
Patrick Neven
Angelo Di Leo
Miguel Martin
Vincent Bours
Joelle Collignon
Dominique Bron
Pierre Freres
Johan Flamaing
Published In
J Geriatr Oncol
Breast Cancer Res Treat
BMC Cancer
Clin Cancer Res
Cancers (Basel)
Affiliations
Soon will be listed here.
Recent Articles
11.
Evaluation of a psychoneurological symptom cluster in patients with breast or digestive cancer: a longitudinal observational study
Gregoire C, Baussard L, Ernst M, Diep A, Faymonville M, Devos M, et al.
BMC Cancer . 2024 Jan; 24(1):51. PMID: 38195471
Background: A psychoneurological symptom cluster composed of cancer-related fatigue, emotional distress, sleep difficulties, and pain is very common among patients with cancer. Cognitive difficulties are also frequently associated with this...
12.
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Goetz M, Hamilton E, Campone M, Hurvitz S, Cortes J, Johnston S, et al.
Clin Cancer Res . 2023 Oct; 30(10):2233-2244. PMID: 37889120
Purpose: To identify potential predictors of response and resistance mechanisms in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated with the cyclin-dependent kinase 4 and 6...
13.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Nakamura Y, Mizuno N, Sunakawa Y, Canon J, Galsky M, Hamilton E, et al.
J Clin Oncol . 2023 Sep; 41(36):5569-5578. PMID: 37751561
Purpose: To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC). Methods: SGNTUC-019...
14.
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
Jerusalem G, Prat A, Salgado R, Reinisch M, Saura C, Ruiz-Borrego M, et al.
Breast . 2023 Sep; 72:103580. PMID: 37741273
Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer. The noncomparative phase...
15.
A Group Intervention Combining Self-Hypnosis and Self-Care in Oncology: Implementation in Daily Life and Perceived Usefulness
Gregoire C, Faymonville M, Vanhaudenhuyse A, Jerusalem G, Monseur J, Bragard I
Int J Clin Exp Hypn . 2023 Sep; 71(4):313-337. PMID: 37682079
Multicomponent mind-body interventions are increasingly studied in oncology to improve patients' quality of life (QOL). However, the respective usefulness of each of their components or their long-term use by the...
16.
End-of-Life Care in the Last Three Months before Death in Older Patients with Cancer in Belgium: A Large Retrospective Cohort Study Using Data Linkage
Depoorter V, Vanschoenbeek K, Decoster L, Silversmit G, Debruyne P, De Groof I, et al.
Cancers (Basel) . 2023 Jul; 15(13). PMID: 37444458
This study aims to describe end-of-life (EOL) care in older patients with cancer and investigate the association between geriatric assessment (GA) results and specialized palliative care (SPC) use. Older patients...
17.
Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium
Depoorter V, Vanschoenbeek K, Decoster L, Silversmit G, Debruyne P, De Groof I, et al.
Lancet Healthy Longev . 2023 Jun; 4(7):e326-e336. PMID: 37327806
Background: Little evidence is available on the long-term health-care utilisation of older patients with cancer and whether this is associated with geriatric screening results. We aimed to evaluate long-term health-care...
18.
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer
Li J, Zhang D, Liu Z, Wang Y, Li X, Wang Z, et al.
Ann Transl Med . 2023 Feb; 11(2):83. PMID: 36819490
Background: Breast cancer is the most common cancer worldwide, and triple-negative breast cancer (TNBC) has the worst prognosis. Standard systemic treatment includes chemotherapy and immunotherapy. Poly ADP-ribose polymerase (PARP) inhibitors...
19.
Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes
Depoorter V, Vanschoenbeek K, Decoster L, De Schutter H, Debruyne P, De Groof I, et al.
J Geriatr Oncol . 2023 Feb; 14(2):101428. PMID: 36804333
Introduction: Geriatric screening and geriatric assessment (GS/GA) have proven their benefits in the care for older patients with cancer. However, less is known about the predictive value of GS/GA for...
20.
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
Barlesi F, Isambert N, Felip E, Cho B, Lee D, Peguero J, et al.
Oncologist . 2022 Dec; 28(3):258-267. PMID: 36571770
Background: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor beta receptor II (a TGF-β "trap") fused to a human immunoglobulin G1...